Login to Your Account



Success With Celgene

What’s the ‘Fourth’ wall? Epizyme’s $25M for proof-of-concept hurdle

By Randy Osborne
Staff Writer

Tuesday, January 7, 2014
The rebound story of the week came via Epizyme Inc., which climbed mightily on news from the Phase I trial with its EPZ-5676 DOT1L histone methyltransferase (HMT) inhibitor, hitting a proof-of-concept milestone and bringing a $25 million payment from collaborator Celgene Corp.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription